Summit Therapeutics
Summit Therapeutics
SMMT
NASDAQ
12.98
USD
-31.03%
About
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule.
It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3).
Its ivonescimab is engineered with Akeso's Tetrabody technology..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 1.7M |
| Three Month Average Volume | 56.8M |
| High Low | |
| Fifty-Two Week High | 14.25 USD |
| Fifty-Two Week Low | 1.52 USD |
| Fifty-Two Week High Date | 23 Aug 2024 |
| Fifty-Two Week Low Date | 08 Sep 2023 |
| Price and Volume | |
| Current Price | 12.98 USD |
| Beta | -1 |
| Relative Price Change | |
| Four Week Relative Price Change | 17.97% |
| Thirteen Week Relative Price Change | 39.64% |
| Twenty-Six Week Relative Price Change | 153.87% |
| Fifty-Two Week Relative Price Change | 539.42% |
| Year-to-Date Relative Price Change | 319.96% |
| Price Change | |
| One Day Price Change | 0.93% |
| Thirteen Week Price Change | 49.45% |
| Twenty-Six Week Price Change | 179.14% |
| Five Day Price Change | -0.76% |
| Fifty-Two Week Price Change | 701.23% |
| Year-to-Date Price Change | 397.32% |
| Month-to-Date Price Change | 20.19% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.11073 USD |
| Book Value Per Share (Most Recent Quarter) | 0.26932 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.10803 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.26673 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.20448 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.99239 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.22986 USD |
| Normalized (Last Fiscal Year) | -0.99239 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.99239 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.22986 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.99239 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.22986 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.26543 USD |
| Cash Per Share (Most Recent Quarter) | 0.44934 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.99207 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.2301 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.13901 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -6,355 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -20,993.76% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -20,611.88% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -20,989.46% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -42.36% |
| Tangible Book Value (5 Year) | 13.91% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -100.00% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -4.84% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -304.46% |
| EPS Change (Trailing Twelve Months) | 86.47% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 120 |
| Price to Tangible Book (Most Recent Quarter) | 47 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -225,469,000 |
| Net Debt (Last Fiscal Year) | -86,242,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 117 |
| Price to Book (Most Recent Quarter) | 48 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 129 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 9 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -76,888,000 |
| Free Cash Flow (Trailing Twelve Months) | -97,614,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -121 |
| Net Interest Coverage (Trailing Twelve Months) | -51 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 129 |
| Total Debt to Equity (Most Recent Quarter) | 51 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -141.83% |
| Return on Assets (Trailing Twelve Months) | -55.83% |
| Return on Assets (5 Year) | -77.32% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -601.85% |
| Return on Equity (Trailing Twelve Months) | -102.77% |
| Return on Equity (5 Year) | -198.65% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -152.22% |
| Return on Investment (Trailing Twelve Months) | -75.71% |
| Return on Investment (5 Year) | -86.35% |